Drugs / GME751
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06153238 | May 2024 → May 2026 | melanoma | Sandoz | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06159790 | Apr 2024 → Mar 2026 | non-small cell lung carcinoma | Sandoz | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GME751 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06159790 ↗ |
| Modality | Protein / enzyme biologic | “Concentrate for solution for infusion, Biologic, Liquid in vial” NCT06159790 ↗ |
| Route | Intravenous | “Subjects will receive GME751 via intravenous (IV) infusion.” NCT06153238 ↗ |